Physician

Abdulla Abdel Hafeez

According to 2025 Medicare claims, Abdulla Hafeez (NPI: 1265663751) practices geriatric medicine in the Detroit-Dearborn-Livonia, MI market, with the plurality of this provider's patient population coming from Wayne, MI. This provider's primary affiliated billing organization is WAFA A ELHASSAN MD PLLC (NPI: 1609425180; TIN: 842446843) and primary practice location at 48124-4089. Hafeez is affiliated with the Arvon CIN (ACO ID: A1095), participating under the MSSP model.

Hafeez's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 696 traditional Medicare patients, billed 4,410 HCPCS/CPT codes, and received $289,299 in Medicare payments. The top billing code was 99223 (Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes). Part D data shows 1,968 prescription claims across 199 beneficiaries totaling $102,271 in drug costs, led by Eliquis (Apixaban). 2023 DME data shows 12 claims. Open Payments data shows 4 records totaling $294. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $139,502 and ending at $289,299. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $141,303 and ending at $102,271. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $10,681 to $1,158.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	423	2,171	$139,502
2016	651	3,396	$219,567
2017	639	3,252	$214,633
2018	737	3,612	$256,161
2019	723	2,886	$211,492
2020	400	1,326	$104,096
2021	452	2,560	$160,130
2022	335	1,559	$101,161
2023	819	5,124	$310,732
2024	696	4,410	$289,299

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	249	2,050	$141,303
2016	331	4,521	$207,259
2017	288	5,057	$242,529
2018	320	5,614	$399,797
2019	214	4,900	$250,249
2020	177	2,735	$156,356
2021	155	1,301	$107,031
2022	269	1,842	$147,703
2023	315	3,758	$267,281
2024	199	1,968	$102,271

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	59	$6,718
2016	18	211	$7,522
2017	N/R	168	$3,755
2018	N/R	136	$4,384
2019	N/R	140	$5,686
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	12	$552
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	223	238	$137
99222	Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes	336	384	$105
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	157	308	$95
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	421	1,619	$63
99231	Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes	181	447	$40

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Eliquis	Apixaban	73	2,379	$43,371
Buprenorphine	Buprenorphine	16	448	$3,253
Lurasidone Hcl	Lurasidone Hcl	16	482	$2,611
Ziprasidone Hcl	Ziprasidone Hcl	13	396	$2,149
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	83	1,913	$1,474

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	4	$294	Otsuka America Pharmaceutical, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Abdulla Abdel Hafeez?

Tedicare shows public-source Medicare data for Abdulla Abdel Hafeez (NPI 1265663751), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Abdulla Abdel Hafeez have ACO affiliation data?

Abdulla Abdel Hafeez is shown with ACO affiliation data for Arvon CIN (MSSP, ACO ID A1095).

What billing organization is linked to Abdulla Abdel Hafeez?

Abdulla Abdel Hafeez is linked to WAFA A ELHASSAN MD PLLC (billing NPI 1609425180) in the available physician profile data.

Does Abdulla Abdel Hafeez have Open Payments data?

Abdulla Abdel Hafeez has 4 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.